|
1. Biologie
|
|
|
|
|
Metabolomics Study Reveals another Energy Source for Cancer Cells [NCI]
|
|
|
|
|
|
Using
new metabolomics technologies, the researchers found that cancer cells
can use the compound lactate to fuel biochemical reactions and to
generate other compounds needed for cell growth, such as lipids to build
new cellular membranes. Metabolomics is the science of measuring small
molecules, such as glucose, amino acids, and cholesterol, within a
biological sample.
|
|
|
|
|
|
|
3.5 Prévention - UV
|
|
|
Doctors think you don’t use enough sunscreen [Reuters]
|
|
|
|
|
|
In
a survey of 156 U.S. dermatologists, every single one of them agreed
that sunscreen reduces premature aging of the skin, or photoaging, and
97 percent agreed that it also lowers the risk of cancer. But 99 percent
of them also think their patients don’t apply enough sunscreen.
|
|
|
|
|
|
|
4.10 Dép., diag. & prono. - FDA, EMA, NICE,...
|
|
|
|
|
|
|
5. Traitements
|
|
|
|
5.10 Traitements - Essais
|
|
|
|
5.12 Immunothérapies
|
|
|
|
A New Immunotherapy Option for Treating Lung Cancer [AACR]
|
|
|
|
|
|
Given
that there are more than 90 clinical trials testing atezolizumab as a
potential treatment for various types of cancer listed on clinical
trials.gov, it is likely that the use of this immunotherapeutic will be
expanded in the future.
|
|
|
|
|
|
|
5.12.1 Immunothérapies - partenariats
|
|
|
|
5.2 Pharma
|
|
|
|
|
Roche bid for Avastin follow-on suffers blow with trial failure [Reuters]
|
|
|
|
|
|
Roche
had been hoping vanucizumab would win approval as a stand-alone
follow-up drug for Avastin, once its U.S. patent protections expire come
2019 and biosimilar copies emerge. But Dan O'Day, head of Roche's
pharmaceuticals division, said the monoclonal antibody did not meet its
primary endpoint -- progression-free survival -- when compared
head-to-head against Avastin in a phase II study against mCRC.
|
|
|
|
|
|
|
5.3 Traitements - FDA, EMA, NICE...
|
|
|
|
FDA official warns other drug makers not to copy Sarepta [STAT]
|
|
|
|
|
|
“First,
we may see companies asking the FDA for approval based on less robust
data sets than have been accepted in the past. “Second, companies may
hope to engage patient advocates in the FDA approval process in a much
more direct way than they have in the past. I wouldn’t be surprised at
all if companies sought to involve themselves more closely with patient
advocacy groups going forward,” Sachs added.
|
|
|
|
|
|
|
|
Opening up clinical data on new medicines [EMA]
|
|
|
|
|
|
“Transparency
on clinical data is a longstanding commitment from EMA and today, we
are delivering on our promise to give access to the data on which our
recommendations are based”, explained EMA’s Executive Director Guido
Rasi.
|
|
|
|
|
|
|
5.3.4 Traitements - AMM (FDA, EMA)
|
|
|
|
New treatment recommended for kidney cancer [NICE]
|
|
|
|
|
|
In
July 2016 the NICE appraisal committee found the trial data on
nivolumab for kidney cancer was immature, which meant the long-term
survival was uncertain. Therefore, it could not be recommended for
routine NHS use. In response the company adjusted their cost-analysis
and proposed a new simple discount patient access scheme for nivolumab.
They also provided data from recently published phase I and phase II
trials, which included longer-term follow-up data on mortality.
|
|
|
|
|
|
|
5.4 Traitements - Economie
|
|
|
|
|
Defining the True Value of Innovation in Cancer Treatment [BMS]
|
|
|
|
|
|
Specifically,
we believe that the primary objective of an accurate and comprehensive
cost-effectiveness analysis, specific to PD-1 immunotherapies, should
properly identify the highest value treatment for each distinct patient.
ICER violates this principle by inappropriately comparing outcomes
among different target populations.
|
|
|
|
|
|
|
Sanders seeks Ariad data on cancer drug price hikes [STAT]
|
|
|
|
|
|
As
we reported previously, Ariad effectively doubled the price of its 15
mg tablet. Until September 2014, a two-month supply, which was 60
tablets, carried a list price of $10,350, but Ariad discontinued sales
of this quantity. Instead, the company began charging the same price for
30 tablets of the 15 mg dose.
|
|
|
|
|
|
|
|
6. Lutte contre les cancers
|
|
|
|
6.10.1 Politiques (USA)
|
|
|
|
|
6.11 Patients
|
|
|
|
6.7 DMP, Big Data & applis
|
|
|
Automating big-data analysis [MIT News]
|
|
|
|
|
|
Developed
by Schreck and Veeramachaneni, the new language, dubbed Trane, should
reduce the time it takes data scientists to define good prediction
problems, from months to days.
|
|
|
|
|
|
|
|
|
6.8 Communication
|
|
|